Safety Profile and Important Considerations for Fat Cell Targeting Understanding how AOD-9604 targets fat cells includes recognizing safety considerations and appropriate precautions
PMID: 29683489
Additionally, B-CQDs administered intravenously localised in kidneys and lymph nodes, intraperitoneally in intestines, liver, heart, and spinal cord, and orally in liver, kidneys, and lymphatic tissue, with peak tissue accumulation occurring at 30 min, and rapid systemic clearance within 2 hours [159]
At 250 mcg per dose, that is 20 doses regardless of water volume
You should also avoid contact with people who have not had chickenpox or who have a weakened immune system
Confirmation bias leads people to interpret ambiguous outcomes favorably when they have invested in a treatment approach